COMBINATION OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND MTOR INHIBITOR

摘要

To provide a method of treating proliferative diseases of mammalian target of rapamycin (mTOR) kinase dependent diseases.SOLUTION: A pharmaceutical composition contains 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, and an mTOR inhibitor selected from RAD rapamycin (sirolimus) and derivatives/analogs thereof such as everolimus or RAD001; CCI-779, ABT578, SAR543, ascomycin (an ethyl analog of FK506), AP23573, AP23841, or compounds that bind to the ATP-binding cleft of mTOR, such as AZD08055 and OSI027.SELECTED DRAWING: None